RxDoctor Payments Data

Ricardo Vega, MD

Pulmonary Disease · Temecula, CANPI 1982607750

Payments from drug & device makers

$115,842in general payments, 2019–2025

Across 102 payments — averaging $1135.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$114K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Actelion Pharmaceuticals US, Inc.$167
  • Lilly USA, LLC$121
  • GSK$115
  • Itamar Medical Inc$78
  • plus $279 from 7 others

What the payments were for

  • Food & beverage$1,74799%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$115,842 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$258,388
Medicare patients
645
Services billed
2,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter505$352,848
Dupixent PenDupilumab33$125,960
Breztri AerosphereBudesonide/Glycopyr/Formoterol159$104,917
Spiriva RespimatTiotropium Bromide113$58,572
Breo ElliptaFluticasone/Vilanterol94$53,132
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr85$45,024
NucalaMepolizumab12$43,582
Stiolto RespimatTiotropium Br/Olodaterol Hcl77$37,556
Fluticasone-SalmeterolFluticasone Propion/Salmeterol154$23,526
Wixela InhubFluticasone Propion/Salmeterol187$22,035
SymbicortBudesonide/Formoterol Fumarate37$11,317
BreynaBudesonide/Formoterol Fumarate50$10,088
Fluticasone Propionate HfaFluticasone Propionate30$7,549
Albuterol Sulfate HfaAlbuterol Sulfate276$7,005
Qvar RedihalerBeclomethasone Dipropionate22$5,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta$115$505,038733 claims
MerckDulera$24$3,72912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →